文献速递乳腺癌

AMEERA-3:阿美奈司特(口服选择性雌激素受体降解剂)对比标准内分泌单药治疗雌激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌的随机II期研究

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
PubMed 文献 · J Clin Oncol · 2023-06-22

AMEERA-3是一项开放标签、全球性II期试验,将290例内分泌治疗后进展的ER+/HER2-晚期乳腺癌患者随机分配至阿美奈司特或医生选择的内分泌单药治疗。主要终点独立中心评估的无进展生存期(PFS)在两组间数值相似(中位PFS 3.6 vs 3.7个月;分层HR 1.051,95%CI 0.789-1.4;单侧P=0.643),研究未达到主要目标。基线ESR1突变患者中阿美奈司特组PFS数值延长(中位PFS 3.7 vs 2.0个月;分层HR 0.9,95%CI 0.565-1.435)。

要点

  • 阿美奈司特对比医生选择内分泌治疗,中位PFS 3.6 vs 3.7个月,分层HR 1.051,未达主要终点。
  • 基线ESR1突变患者中,阿美奈司特组中位PFS 3.7 vs 2.0个月,分层HR 0.9。
  • 阿美奈司特组任何级别治疗中出现的不良事件发生率82.5% vs 76.2%,≥3级事件21.7% vs 15.6%。

核心结论

  • AMEERA-3未达到阿美奈司特对比医生选择内分泌治疗改善PFS的主要目标,但基线ESR1突变患者中观察到PFS数值改善。
  • 阿美奈司特的疗效和安全性与人表皮生长因子受体2阴性晚期乳腺癌二线/三线内分泌治疗的标准治疗一致。

研究设计与样本

  • AMEERA-3是一项开放标签、全球性II期试验(ClinicalTrials.gov标识符:NCT04059484)。
  • 入组患者为ER+/HER2-晚期乳腺癌,在(新)辅助或晚期阶段不超过两线内分泌治疗后进展。
  • 患者按1:1随机分配至阿美奈司特或医生选择的单药内分泌治疗,按内脏转移有/无、既往环依赖性激酶4/6抑制剂治疗有/无、美国东部肿瘤协作组体能状态(0/1)分层。
  • 主要终点为独立中心评估的无进展生存期,采用分层对数秩检验比较(单侧I类错误率2.5%)。
  • 2019年10月22日至2021年2月15日期间,290例患者被随机分配至阿美奈司特组(n=143)或医生选择治疗组(n=147)。

主要发现

  • 阿美奈司特组与医生选择治疗组的中位PFS分别为3.6个月与3.7个月,分层HR 1.051(95%CI 0.789-1.4),单侧P=0.643。
  • 基线ESR1突变患者(280例中120例)中,阿美奈司特组与医生选择治疗组的中位PFS分别为3.7个月与2.0个月,分层HR 0.9(95%CI 0.565-1.435)。
  • 总生存数据尚不成熟,两组间数值相似(HR 0.913;95%CI 0.595-1.403)。
  • 阿美奈司特组与医生选择治疗组任何级别治疗中出现的不良事件发生率分别为82.5%与76.2%,≥3级事件发生率分别为21.7%与15.6%。

关键数值与推荐

  • 主要终点PFS:阿美奈司特组中位PFS 3.6个月 vs 医生选择治疗组3.7个月(分层HR 1.051,95%CI 0.789-1.4;单侧P=0.643)。
  • 基线ESR1突变亚组:阿美奈司特组中位PFS 3.7个月 vs 医生选择治疗组2.0个月(分层HR 0.9,95%CI 0.565-1.435)。
  • 总生存:HR 0.913(95%CI 0.595-1.403),数据不成熟。
  • 安全性:任何级别治疗中出现的不良事件阿美奈司特组82.5% vs 医生选择治疗组76.2%;≥3级事件21.7% vs 15.6%。

临床怎么用

  • 原文结论指出AMEERA-3未达到改善PFS的主要目标,但基线ESR1突变患者中观察到PFS数值改善。
  • 原文结论指出阿美奈司特的疗效和安全性与人表皮生长因子受体2阴性晚期乳腺癌二线/三线内分泌治疗的标准治疗一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (aBC). PATIENTS AND METHODS: In AMEERA-3 (ClinicalTrials.gov identifier: NCT04059484), an open-label, worldwide phase II trial, patients with ER+/HER2- aBC who progressed in the (neo)adjuvant or advanced settings after not more than two previous lines of endocrine therapy (ET) were randomly assigned 1:1 to amcenestrant or single-agent endocrine treatment of physician's choice (TPC), stratified by the presence/absence of visceral metastases, previous/no treatment with cyclin-dependent kinase 4/6 inhibitor, and Eastern Cooperative Oncology Group performance status (0/1). The primary end point was progression-free survival (PFS) by independent central review, compared using a stratified log-rank test (one-sided type I error rate of 2.5%). RESULTS: Between October 22, 2019, and February 15, 2021, 290 patients were randomly assigned to amcenestrant (n = 143) or TPC (n = 147). PFS was numerically similar between amcenestrant and TPC (median PFS [mPFS], 3.6 v 3.7 months; stratified hazard ratio [HR], 1.051 [95% CI, 0.789 to 1.4]; one-sided P = .643). Among patients with baseline mutated ESR1; (n = 120 of 280), amcenestrant numerically prolonged PFS versus TPC (mPFS, 3.7 v 2.0 months; stratified HR, 0.9 [95% CI, 0.565 to 1.435]). Overall survival data were immature but numerically similar between groups (HR, 0.913; 95% CI, 0.595 to 1.403). In amcenestrant versus TPC groups, treatment-emergent adverse events (any grade) occurred in 82.5% versus 76.2% of patients and grade ≥3 events occurred in 21.7% versus 15.6%. CONCLUSION: AMEERA-3 did not meet its primary objective of improved PFS with amcenestrant versus TPC although a numerical improvement in PFS was observed in patients with baseline ESR1 mutation. Efficacy and safety with amcenestrant were consistent with the standard of care for second-/third-line ET for ER+/HER2- aBC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tolaney SM, Chan A, Petrakova K, et al. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol. 2023. PMID: 37348019. doi:10.1200/JCO.22.02746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。